Abstract

Aim: To find out the efficacy of macular photocoagulation when given in the early or late period after single intravitreal bevacizumab injection in terms of central foveal thickness change and visual acuity gain.

Methods: 40 patient eyes were studied and they were divided into groups based on sex, age, hba1c levels, severity of disease and treatment received over the period of 6 months.

Result and Conclusion: Patients receiving deferred macular photocoagulation after a single intravitreal injection of bevacizumab had better outcomes regarding reduction of central foveal thickness and improvement in visual acuity at the end of 6 month observation period compared to those patients receiving prompt macular photocoagulation.

Keywords: Bevacizumab; Laser Photocoagulation; Diabetic Retinopathy; Central Foveal Thickness; Clinically Significant Macular Edema

References

1. Gale Jason. "India’s Diabetes Epidemic Cuts Down Millions Who Escape Poverty". Bloomberg (2010).
2. Goldberg MF and Jampol LM. “Knowledge of diabetic retinopathy before and 18 years after the Airlie House Symposium on Treatment of Diabetic Retinopathy”. Ophthalmology 94 (1987): 741-746.
3. “Early treatment diabetic retinopathy study research group: photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 9”. Ophthalmology 98 (1991): 766-0-785.
4. Yasser M Helmy and Heba R Atta Allah. “Optical coherence tomography classification of diabetic cystoid macular edema”. Clinical Ophthalmology 7 (2013): 10.
5. Asensio-Sánchez VM., et al. “Microalbuminuria and diabetic retinopathy”. Archivos de la Sociedad Española de Oftalmología 2 (2008): 85.
6. Aksoy S., et al. “Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema”. International Journal of Ophthalmology3 (2015): 550-555.
7. Arevalo JF., et al. “Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up”. Ophthalmology 4 (2007): 743-750.
8. Takamura Y., et al. “The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection”. Investigative Ophthalmology and Visual Science 8 (2014): 4741-4746.
9. Heier J., et al. “Comparative Effectiveness Panel. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice”. JAMA Ophthalmology 29 (2015): 1-6.
10. Barteselli G., et al. “Results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation”. British Journal of Ophthalmology.
11. Javanović S., et al. “Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema”. 72.10 (2015).
12. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology7 (1981): 583-600.
13. Solaiman KA., et al. “Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema”. Retina 10 (2010): 1638-1645.

Citation

Citation: Vidhi Solanki., et al. “To Study the Effect on Central Foveal Thickness Following Prompt/Deferred Macular Photocoagulation After Single Intravitreal Bevacizumab Injection". Acta Scientific Ophthalmology 3.11 (2020): 27-32.

Copyright

Copyright: © 2020 Vidhi Solanki., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.